BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Pfizer's COVID-19 vaccine provides protection against the highly contagious variant of the virus that emerged in South Africa, a new study shows. People who received the Pfizer shots had higher levels of antibodies capable of neutralizing the strain than those found in patients who contracted the bug, New York University researchers found.

Pfizer COVID-19 vaccine should ward off South Africa strain, study shows

Payout is biggest in history of Munich-based venture-capital fund MIG Fonds.

These early BioNTech investors just saw their faith rewarded with a $719 million payday

According to Reuters, Pfizer Inc ((NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) have reportedly withdrawn their application for the emergency-use nod of its COVID-19 vaccine in India, as the Company failed to meet drug regulator's (Central Drugs Standard Control Organization) demand for small local trial on the vaccine's safety and immunogenicity for Indians. Unlike other companies conducting small studies in India for foreign-developed vaccines, Pfizer had sought an exception citing approvals it had received elsewhere based on trials in countries such as the U.S. and Germany.

Pfizer Drops India Vaccine Application After Regulator Seeks Local Trial - Reuters

People who were previously infected with coronavirus were more likely to report having full-body reactions.

More Than One In Three People In U.K. Study Report Side Effects From Pfizer Coronavirus Vaccine

Moderna

Novavax

Should Investors Worry About New Coronavirus Variants?

The staggering stat was revealed Tuesday in a financial forecast from the Manhattan-based drugmaker, which said its revenue for the year would range between $59 billion and $61 billion.

Pfizer expects $15 billion in COVID-19 vaccine sales in 2021

Investors weren't impressed with the results, despite double-digit percentage increases on both the top and bottom lines.

Coronavirus Vaccine Maker Pfizer Posts a Mixed Q4

Pfizer CEO Albert Bourla says he has grown more confident about the outlook for the vaccine.

Pfizer Increased Vaccine Sales Estimate After AstraZeneca and J&J Stumbles

Pfizer stock took a hit in early February on a disappointing fourth-quarter report, though the company called for $15 billion in full-year Covid vaccine sales. So, is Pfizer stock a buy now?

Is Pfizer Stock A Buy On Guidance For $15 Billion In Covid Vaccine Sales?

AMC Entertainment

Amazon

GameStop

Alphabet

SPDR S&P 500 ETF Trust

We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.

Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS

Pfizer Inc. (NYSE: PFE), the first company to obtain emergency use authorization for a coronavirus vaccine, offered a preview Tuesday into the vaccine's revenue potential in the current fiscal year. Pfizer's COVID-19 vaccine was co-developed with German partner BioNTech SE – ADR (NASDAQ: BNTX).

Pfizer Expects COVID-19 Vaccine To Bring $15B In Revenue This Year

Pfizer expects to earn approximately $15 billion in revenue from its Covid-19 vaccine this year, the company said Tuesday.

Pfizer expects to rake in sales of $15 billion from its Covid-19 vaccine this year

Pfizer is planning to deliver 200 million doses of its coronavirus vaccine to the U.S. by May, earlier than its initial forecast of July.

Pfizer plans to deliver 200 million doses of Covid vaccine to U.S. by May, sooner than expected

US pharmaceutical giant Pfizer expects the coronavirus vaccine it developed with BioNTech, the first to be authorized for emergency use in the West, to make it about $15 billion in revenues in 2021. The company expects to produce up to 2 billion doses of the vaccine in 2021, based on its updated six-dose label, it said Tuesday. By January 31, it had already supplied 65 million doses of its vaccine globally, with close to half going to the US.

Pfizer expects to make $15 billion in sales from its COVID-19 vaccine in 2021

German chancellor Angela Merkel set to hold crisis talks on Monday to boost faltering vaccination program

BioNTech-Pfizer partnership pledges 75 million more vaccine doses to help ease the EU bloc's shortage

Shares of BioNTech SE gained 0.9% in premarket trading on Monday after the company told investors that it nearly doubled its estimate for the amount of coronavirus vaccine it plans to produce in 2021. BioNTech said in a regulatory filing that it now expects to manufacture 2 billion doses of its COVID-19 vaccine this year, up from previous estimates of 1.3 billion.

BioNTech now plans to produce 2 billion doses of its COVID-19 vaccine in 2021

New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models from Pfizer and BioNTech's mRNA-based vaccine candidates, BNT162b1 and BNT162b2, for the prevention of COVID-19 were published in the journal Nature . Some of these data were initially made available to the public on September 9, 2020 via the online preprint server, bioRxiv . For additional details, please read the previously issued press release .

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

Johnson & Johnson

Which Is the Best COVID Vaccine Stock: Pfizer, BioNTech, Moderna, Johnson & Johnson, or Novavax?

An experimental coronavirus vaccine from Johnson & Johnson is 66% effective at preventing moderate to severe COVID-19, according to new trial data the company released on Friday.  At first glance, the vaccine doesn't appear to be as stellar as authorized vaccines from Pfizer and Moderna, but it does have a few perks.

How does Johnson & Johnson's COVID-19 vaccine stack up against shots from Pfizer and Moderna?

Sanofi

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

Fate Therapeutics

These two companies are at the forefront of innovation during our golden age of biotech.

2 Best Biotech Stocks to Buy in January

Which stock will be the bigger winner between these two COVID-19 vaccine partners?

Better Buy: Pfizer vs. BioNTech

Pfizer will continue to supply its COVID-19 vaccine to Italy, respecting its agreement with the European Commission, even if Rome sues the company, the chief executive of the group's Italian unit said on Thursday.

Pfizer to continue vaccine supply to Italy even if Rome files lawsuit: CEO to paper

Unusual collaboration will see Sanofi supply more than 125 million doses of Pfizer–BioNTech COVID shot from the summer.

Sanofi teams up with BioNTech and Pfizer to help fix Europe's vaccine shortage

Sweden has said that it is withholding payment to the pharma giant Pfizer while it figures out if it is being overcharged for coronavirus vaccine doses. On Tuesday, the Dagens Nyheter newspaper reported that Sweden's health agency asked the European Union to ask Pfizer why it was being charged for six doses per vial of the Pfizer-BioNTech vaccine, despite only agreeing to pay for five.

News for BioNTech SE Stock (BNTX)